Sensyne Health plc
https://www.sensynehealth.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sensyne Health plc
Spanish Team’s AI Model For Pandemic Response Named XPRIZE Winner
VALENCIA IA4COVID19’s AI model won the XPRIZE Pandemic Response Challenge grand prize. Researchers are pinning their hopes on AI to help predict the next pandemic, but also for early diagnosis of COVID-19.
Digital Health Roundup, January/February 2021: The Continued Rise Of AI, Telehealth
In this new roundup feature focusing on the most notable developments in digital health, we pick the key news from the year so far.
Early-Stage R&D In The Spotlight As BMS Patent Expirations Approach
With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.
Sensyne Partners With Excalibur To Improve Usability Of COVID-19 Tests
Sensyne has licensed its MagnifEye artificial intelligence technology to Excalibur Healthcare to improve the detection of COVID-19 infection at low viral loads.
Company Information
- Industry
- Digital Health
- Pharmaceuticals
- Services
-
Medical Devices
- Monitoring Equipment & Devices
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Drayson Health Ltd